Philogen who? A low profile but pharma-connected Italian-Swiss hybrid steps out with $68M for a final push over the PhIII finish line
Philogen is one of the best connected late-stage biotechs you’ve probably never heard of.
Founded by three brothers — the businessman and company CEO Duccio Neri and his two scientist siblings, Dario and Giovanni — way back in 1996, Philogen has been building up its expertise in armed antibodies over the past 23 years. It’s struck multiple development pacts with a whole range of pharma giants, occasionally rather casually and briefly noting them in abbreviated releases — like the three it announced in January with Novartis, J&J and Celgene, shorn of any specifics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.